Close Menu

chromosomal abnormalities

The deal will allow LifeLabs to perform Natera's Panorama NIPT in Canada and follows a prior agreement for LifeLabs to distribute the test in that country.

Three new studies, published online in the New England Journal of Medicine, shed light on how NIPT may be best integrated into clinical care for all pregnant women.

The Swiss firm is paying $260,000 for InKaryo and will assume its $280,000 convertible bond debt obligation.

NEW YORK (GenomeWeb News) – Sequenom and CombiMatrix today announced an agreement to market chromosomal microarray analysis testing services "to broaden and confirm the results of non-invasive prenatal testing" to doctors and patients.

NEW YORK (GenomeWeb News) – Looking to enter the fast-growing non-invasive prenatal diagnostics space, CellScape is eyeing a second-half 2014 commercial launch of its test, which detects for fetal aneuploidies, and more importantly, genetic disorders that currently require invasive methods for de

Illumina and Kindstar Global announced last week that they have made an agreement that allows Kindstar to offer a set of Illumina products, including the Infinium Dx CytoSNP-12 BeadChip assay, to its Chinese clients.

Life Technologies will sell the kits for chromosomal abnormalities under the Applied Biosystems name. The agreement, however, does not include the US.

The settlement, which will be funded by insurance proceeds, relates to a lawsuit filed in November by Sequenom's shareholders alleging mishandling of data surrounding the company's SEQureDx test.

Pages

NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.

According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.

A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.

In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.